BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
- Conditions
- Bladder Cancer
- Registration Number
- NCT00023842
- Brief Summary
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop tumor cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with biological therapy may kill more tumor cells. It is not yet known if BCG is more effective with or without mitomycin.
PURPOSE: Randomized phase II trial to compare the effectiveness of BCG plus mitomycin with that of BCG alone in treating patients who have bladder cancer.
- Detailed Description
OBJECTIVES:
* Compare the complete response rate of patients with carcinoma in situ of the bladder treated with adjuvant intravesical BCG with or without intravesical mitomycin following transurethral resection.
* Compare the disease-free interval and type of recurrence after complete response in patients treated with these regimens.
* Compare the side effects of these regimens in these patients.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to one of two treatment arms.
Arm I:
* Induction therapy: Patients receive intravesical mitomycin over 1 hour once weekly on weeks 1-6 and intravesical BCG once weekly on weeks 7-12. Patients with visible lesions or disease recurrence or progression undergo transurethral resection (TUR) during weeks 16-18 and receive one additional course of intravesical therapy.
* Maintenance therapy:Patients with a complete response after either course of induction therapy proceed to maintenance therapy comprising intravesical mitomycin once on week 1 and intravesical BCG once weekly on weeks 2 and 3. Maintenance therapy repeats every 6 months through year 3.
Arm II:
* Induction therapy:Patients receive intravesical BCG once weekly on weeks 1-6 and 10-12. Patients with visible lesions or disease recurrence or progression undergo transurethral resection (TUR) during weeks 16-18 and receive one additional course of intravesical therapy.
* Maintenance therapy: Patients with a complete response after either course of induction therapy receive maintenance therapy comprising intravesical BCG once weekly on weeks 1-3. Maintenance therapy repeats every 6 months through year 3.
Patients are followed every 6 months for 5 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 84-126 patients (42-63 per treatment arm) will be accrued for this study within 3.5 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 97
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (16)
Virga Jesse Hospital
🇧🇪Hasselt, Belgium
Universitair Ziekenhuis Gent
🇧🇪Ghent, Belgium
Ospedale di Circolo e Fondazione Macchi
🇮🇹Varese, Italy
Azienda Ospedaliera Maggiore Della Carita
🇮🇹Novara, Italy
Dokuz Eylul University School of Medicine
🇹🇷Izmir, Turkey
Onze Lieve Vrouw Ziekenhuis Aalst
🇧🇪Aalst, Belgium
Academisch Ziekenhuis der Vrije Universiteit Brussel
🇧🇪Brussels, Belgium
Cazk Groeninghe - Campus Maria's Voorzienigheid
🇧🇪Kortrijk, Belgium
Academisch Ziekenhuis Maastricht
🇳🇱Maastricht, Netherlands
Daniel Den Hoed Cancer Center at Erasmus Medical Center
🇳🇱Rotterdam, Netherlands
Universita Degli Studi Di Pisa
🇮🇹Pisa, Italy
Academisch Medisch Centrum
🇳🇱Amsterdam, Netherlands
University Medical Center Nijmegen
🇳🇱Nijmegen, Netherlands
Hospital Desterro
🇵🇹Amadora, Portugal
University of Wales College of Medicine
🇬🇧Cardiff, Wales, United Kingdom
Bristol Royal Infirmary
🇬🇧Bristol, England, United Kingdom